Supernus Pharmaceuticals Files 8-K on Financials
Ticker: SUPN · Form: 8-K · Filed: 2024-10-21T00:00:00.000Z
Sentiment: neutral
Topics: financial-reporting, 8-K
Related Tickers: SUPN
TL;DR
SUPN filed an 8-K on 10/21/24 covering financials. No major news yet.
AI Summary
On October 21, 2024, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, along with financial statements and exhibits. No specific financial figures or significant events were detailed in the provided text excerpt.
Why It Matters
This filing provides an update on Supernus Pharmaceuticals' operational and financial status, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — The provided text is a standard 8-K filing notification and does not contain specific material events or financial data that would indicate a change in risk.
Key Players & Entities
- Supernus Pharmaceuticals, Inc. (company) — Registrant
- October 21, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Rockville, MD (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Supernus Pharmaceuticals, Inc.?
The primary purpose of this 8-K filing is to report on the company's Results of Operations and Financial Condition, as well as to provide Financial Statements and Exhibits.
On what date was this 8-K filing made or reported as of?
The filing was made as of October 21, 2024, and the date of the earliest event reported is also October 21, 2024.
What is Supernus Pharmaceuticals, Inc.'s state of incorporation?
Supernus Pharmaceuticals, Inc. is incorporated in Delaware.
Where are Supernus Pharmaceuticals, Inc.'s principal executive offices located?
The principal executive offices of Supernus Pharmaceuticals, Inc. are located at 9715 Key West Ave, Rockville, MD 20850.
Does the provided text detail any specific financial results or significant events?
No, the provided text is an excerpt from the 8-K filing's header and does not detail specific financial results or significant events.
Filing Stats: 491 words · 2 min read · ~2 pages · Grade level 9.2 · Accepted 2024-10-21 16:48:11
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share SUPN The Nasdaq Sto
Filing Documents
- supn-20241021.htm (8-K) — 27KB
- ex99110-21x2024.htm (EX-99.1) — 9KB
- image_0a.jpg (GRAPHIC) — 5KB
- 0001356576-24-000060.txt ( ) — 166KB
- supn-20241021.xsd (EX-101.SCH) — 2KB
- supn-20241021_lab.xml (EX-101.LAB) — 21KB
- supn-20241021_pre.xml (EX-101.PRE) — 12KB
- supn-20241021_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On October 21, 2024, Supernus Pharmaceuticals, Inc. issued a press release announcing that it expects to report its business results for the third quarter 2024 after the market closes on Monday, November 4, 2024. The Company will host a conference call and webcast on Monday, November 4, 2024 at 4:30 p.m. E.T. to discuss its third quarter 2024 business and financial results. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Description 99.1 Press Release dated October 21 , 2024 filed as an Exhibit pursuant to Item 2.02 hereof. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SUPERNUS PHARMACEUTICALS, INC. DATED: October 21, 2024 By: /s/ Timothy C. Dec Timothy C. Dec Senior Vice President and Chief Financial Officer 3